Pharma Focus Asia

Resonant Therapeutics Announces Advancement in Collaboration With Janssen

Friday, September 17, 2021

Resonant Therapeutics, Inc., a biotechnology company focused on cancer therapeutic discovery based on unique insights into the tumor microenvironment, today announced that the company has advanced into the next phase of its ongoing agreement with Janssen Research and Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Resonant is a resident of Johnson & Johnson Innovation -- JLABS @ TMC, a premier life science incubator program.

“We are excited that our collaboration has yielded actionable data and novel therapeutic targets,” said John K. Westwick, Ph.D., CEO of Resonant. “Our IMPACT platform, rapidly growing database, and data science capabilities have generated hundreds of novel targets and dozens of unique antibody candidates.”

Under terms of the previously announced agreement, Resonant utilized its tumor-microenvironment IMPACT platform along with cells from difficult-to-treat cancers to identify large candidate target pools. Resonant also utilized its proprietary database and data science strategies to refine and prioritize candidates to yield optimal therapeutic targets. Resonant is eligible to receive additional funding upon targets licensed as a result of the collaboration.

Dr. Westwick continued, “Resonant’s tumor-microenvironment IMPACT platform discovers, validates and prioritizes novel oncology targets and antibody therapeutics with unprecedented speed. We look forward to additional commercial partnerships that leverage these capabilities.”

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024